Sanofi: Odyssey Outcomes investigators highlight at Aha that Praluent ...

Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL PARIS and Tarrytown, N.Y. - November 11, 2018 - New analyses on mortality from the 18,924-patient ODYSSEY OUTCOMES trial were presented at the American Heart Association Scientific Sessions 2018. PraluentA was associated with fewer deaths from any cause among patients who had previously experienced a heart attack or unstable angina , and this was enhanced in patients who were followed for at least 3 years and those who had an LDL-C of 100 mg/dL or higher at baseline.
http://www.globenewswire.com/news-release/2018/11/11/1649346/0/en/Sanofi-ODYSSEY-OUTCOMES-investigators-highlight-at-AHA-that-Praluent-alirocumab-was-associated-with-fewer-deaths-from-any-cause.html